Literature DB >> 17937596

The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.

Matthew D Hall1, Mitsunori Okabe, Ding-Wu Shen, Xing-Jie Liang, Michael M Gottesman.   

Abstract

The platinum (Pt) drugs cisplatin and carboplatin are heavily employed in chemotherapy regimens; however, similar to other classes of drugs, a number of intrinsic and acquired resistance mechanisms hamper their effectiveness. The method by which Pt drugs enter cells has traditionally been attributed to simple passive diffusion. However, recent evidence suggests a number of active uptake and efflux mechanisms are at play, and altered regulation of these transporters is responsible for the reduced accumulation of drug in resistant cells. This review suggests a model that helps reconcile the disparate literature by describing multiple pathways for Pt-containing drugs into and out of the cell.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17937596     DOI: 10.1146/annurev.pharmtox.48.080907.180426

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  136 in total

1.  Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator.

Authors:  Johnny Moretto; Bruno Chauffert; François Ghiringhelli; Janice R Aldrich-Wright; Florence Bouyer
Journal:  Invest New Drugs       Date:  2010-06-10       Impact factor: 3.850

Review 2.  Bugs, drugs and chemical genomics.

Authors:  Terry Roemer; Julian Davies; Guri Giaever; Corey Nislow
Journal:  Nat Chem Biol       Date:  2011-12-15       Impact factor: 15.040

3.  RAB8 enhances TMEM205-mediated cisplatin resistance.

Authors:  Ding-Wu Shen; Michael M Gottesman
Journal:  Pharm Res       Date:  2011-10-04       Impact factor: 4.200

4.  Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.

Authors:  Ding-Wu Shen; Jichun Ma; Mitsunori Okabe; Guofeng Zhang; Di Xia; Michael M Gottesman
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

5.  A novel screening method for transition metal-based anticancer compounds using zebrafish embryo-larval assay and inductively coupled plasma-mass spectrometry analysis.

Authors:  Brittany F Karas; Leonor Côrte-Real; Cathleen L Doherty; Andreia Valente; Keith R Cooper; Brian T Buckley
Journal:  J Appl Toxicol       Date:  2019-04-08       Impact factor: 3.446

6.  Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction.

Authors:  Xue Xue; Song You; Qiang Zhang; Yan Wu; Guo-Zhang Zou; Paul C Wang; Yu-Liang Zhao; Yan Xu; Lee Jia; Xiaoning Zhang; Xing-Jie Liang
Journal:  Mol Pharm       Date:  2012-02-13       Impact factor: 4.939

7.  Genome-wide single-nucleotide resolution of oxaliplatin-DNA adduct repair in drug-sensitive and -resistant colorectal cancer cell lines.

Authors:  Courtney M Vaughn; Christopher P Selby; Yanyan Yang; David S Hsu; Aziz Sancar
Journal:  J Biol Chem       Date:  2020-04-16       Impact factor: 5.157

Review 8.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Authors:  Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

9.  Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.

Authors:  Matthew D Hall; Katherine A Telma; Ki-Eun Chang; Tobie D Lee; James P Madigan; John R Lloyd; Ian S Goldlust; James D Hoeschele; Michael M Gottesman
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

10.  The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.

Authors:  Christopher A Larson; Brian G Blair; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2008-11-07       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.